Tevimbra by BeiGene for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Exploring the relationship between evolvability and species divergence

Ever since Darwin published his landmark theory of how species evolve, biologists have been fascinated with the intricate mechanisms that make evolution possible.

May 11, 2024

MWC Barcelona 2025: Maximizing 5G network value in the age of AI – Pharmaceutical Technology

Li Peng, Huawei’s Corporate Senior Vice President and President of ICT Sales & Service, speaking at MWC Barcelona 2025. Li predicts that symbiosis between 5G-A

March 5, 2025

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.